Liquidia Technologies News Releases http://investors.liquidia.com/ Liquidia Technologies News Releases en Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer http://investors.liquidia.com/news-releases/news-release-details/liquidia-appoints-seasoned-biopharmaceutical-industry-executive RESEARCH TRIANGLE PARK, N.C. , May 22, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz , M.D., as Chief Financial Officer (CFO). Dr. Wed, 22 May 2019 16:30:00 -0400 Liquidia Technologies News Releases 7296 Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019 http://investors.liquidia.com/news-releases/news-release-details/liquidia-announces-poster-presentation-american-thoracic-society To include highlights of the safety and tolerability of LIQ861 at two months of treatment in the INSPIRE Phase 3 Trial RESEARCH TRIANGLE PARK, N.C. , May 14, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today Tue, 14 May 2019 16:15:00 -0400 Liquidia Technologies News Releases 7286 Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-reports-first-quarter-2019-financial Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating P ulmonary Arterial Hypertension On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary Print® Technology Management to Host Webcast and Conference Thu, 02 May 2019 07:00:00 -0400 Liquidia Technologies News Releases 7266 Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019 http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-report-first-quarter-2019-financial RESEARCH TRIANGLE PARK, N.C. , April 23, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”),  a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the Tue, 23 Apr 2019 16:05:00 -0400 Liquidia Technologies News Releases 7251 Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-presents-phase-3-trial-data-liq861-ishlt Positive Data from INSPIRE Trial Continues to Highlight Safety and Tolerability Along with Improvement in Quality of Life Metrics from LIQ861 RESEARCH TRIANGLE PARK, N.C. , April 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical Wed, 03 Apr 2019 16:30:00 -0400 Liquidia Technologies News Releases 7236 Liquidia Technologies to Present at Needham Healthcare Conference http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-present-needham-healthcare-conference RESEARCH TRIANGLE PARK, N.C. , April 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the Tue, 02 Apr 2019 08:00:00 -0400 Liquidia Technologies News Releases 7226 Liquidia Technologies Announces Closing of Offering of Common Stock http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-announces-closing-offering-common-stock RESEARCH TRIANGLE PARK, N.C. , March 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the Mon, 25 Mar 2019 10:54:00 -0400 Liquidia Technologies News Releases 7206 Liquidia Technologies Announces Pricing of Offering of Common Stock http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-announces-pricing-offering-common-stock RESEARCH TRIANGLE PARK, N.C. , March 21, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the Thu, 21 Mar 2019 07:56:00 -0400 Liquidia Technologies News Releases 7191 Liquidia Technologies Announces Proposed Offering of Common Stock http://investors.liquidia.com/news-releases/news-release-details/liquidia-technologies-announces-proposed-offering-common-stock RESEARCH TRIANGLE PARK, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the Mon, 18 Mar 2019 16:45:00 -0400 Liquidia Technologies News Releases 7176 Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension http://investors.liquidia.com/news-releases/news-release-details/liquidias-liq861-meets-primary-endpoint-pivotal-phase-3-inspire •  LIQ861 was well-tolerated in PAH patients at two months of treatment •  INSPIRE enrollment complete, including PK sub-study •  Anticipate submitting NDA for LIQ861 to the FDA in late 2019 RESEARCH TRIANGLE PARK, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. Mon, 11 Mar 2019 03:00:00 -0400 Liquidia Technologies News Releases 7156